Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2022-04-29 Environmental & Social …
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
2021 Environmental, Social and Governance Report
Environmental & Social Information Classification · 95% confidence The document is a detailed report covering Environmental, Social, and Governance (ESG) topics for Pharmaron Beijing Co., Ltd. It includes sections on ESG governance, performance highlights, environmental management, social responsibility, and governance structure. The report references compliance with ESG reporting guidelines from HKEX and Shenzhen Stock Exchange, and it covers a full calendar year (January 1 to December 31, 2021). The content is substantive and comprehensive, not merely an announcement or summary. This matches the description of an Environmental & Social Information report (ESG report). Therefore, the appropriate classification is 'SR' (Environmental & Social Information). The document length (15,000 characters) and detailed content support a high confidence score.
2022-04-29 English
2021 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is a comprehensive report from Pharmaron Beijing Co., Ltd. covering the full fiscal year ended December 31, 2021. It includes detailed sections such as Chairman's Statement, Financial Highlights, Management Discussion and Analysis, Corporate Governance Report, Directors' Report, Independent Auditor's Report, and full consolidated financial statements with notes. The presence of these detailed financial statements and extensive management commentary indicates this is a full annual report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2021
2022-04-29 English
2022 FIRST QUARTERLY REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 FIRST QUARTERLY REPORT' and contains detailed financial data for the first quarter of 2022, including revenue, net profit, earnings per share, assets, liabilities, and segment performance. It explicitly states it is a quarterly report and includes comprehensive financial statements and analysis. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The document is not an announcement of a report publication, nor is it a certification or a short summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-28 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-26 English
(I) PROPOSED GRANT OF CONVERTIBLE BONDS-RELATED SPECIFIC MANDATE TO ISSUE ADDITIONAL H SHARES (II) SUPPLEMENTAL RESOLUTION RELATING TO THE 2021 PROFIT DISTRIBUTION PLAN
Capital/Financing Update Classification · 95% confidence The document is an announcement from Pharmaron Beijing Co., Ltd. regarding the proposed grant of a convertible bonds-related specific mandate to issue additional H shares and a supplemental resolution relating to the 2021 profit distribution plan. It discusses board resolutions, shareholder approvals to be sought at the AGM and class meetings, details about convertible bonds, share issuance, and profit distribution plans. The document is an announcement of proposals and resolutions to be considered at the AGM, not the AGM materials themselves or the results of voting. It is also not a full financial report or earnings release but rather a corporate announcement related to capital structure and shareholder meeting proposals. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to issuance of shares and convertible bonds mandates.
2022-04-20 English
FURTHER ANNOUNCEMENT PROFIT FORECAST IN RELATION TO ACQUISITION OF 100% EQUITY INTEREST IN ANIKEEPER
Regulatory Filings Classification · 95% confidence The document is a detailed announcement related to a profit forecast concerning the acquisition of 100% equity interest in a company (Beijing Anikeeper Biotech Co., Ltd.). It references compliance with specific Listing Rules (Rules 14A.06(32), 14.61, 14A.68(7), 14.60A, and 14.62) of the Hong Kong Stock Exchange, which govern profit forecasts and connected transactions. The document includes a valuation report, assumptions underlying the valuation, and a report from the company's reporting accountants (Ernst & Young) on the arithmetical accuracy of the forecast calculations. It also contains a letter from the Board confirming the forecast and compliance with the Listing Rules. The document is not a full financial report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. It is a regulatory announcement related to a profit forecast in connection with an acquisition, which is a type of regulatory filing. Given the detailed nature and regulatory context, but not being a full financial report, the best classification is Regulatory Filings (RNS).
2022-04-19 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.